Stocks to Sell

Stocks can plunge for any number of reasons — investors may need to raise cash for large milestone purchases, or algorithms could be triggered by stop losses which create massive selloffs. Whatever the case, InvestorPlace’s journalists weed out the markets’ losers, keeping you informed of which stocks to cash out of before they come crashing down.

Virgin Galactic’s Path to Profitability Is Too Uncertain

By Tom Kerr, InvestorPlace Contributor
Will enough people actually want to pay $450,000 for a ticket to space for SPCE stock to take off? Right now, it's hard to say.

A Four-Fingered Hand Gesture Has Lucid Motors Fans Tilting at Windmills

By Joanna Makris, Head of Equity Research, Boardroom Alpha
A cryptic hand gesture by Lucid Motors CEO Peter Rawlinson has the Twittersphere on fire. Here's what we do and don't know about LCID stock.

Duolingo Is Riding a Wave of Language Learning But DUOL Stock Is Too High

By Mark R. Hake, CFA
Duolingo is riding a wave of language learning but DUOL stock Is too high. DUOL stock is likely to lose value as the company's QoQ sales growth is just 27%, and at 10 times it's worth just 35% less.

ContextLogic Stock Faces Key Test After Double Miss Quarterly Results

By Bret Kenwell, InvestorPlace Contributor
ContextLogic is plunging on poor earnings results. Now there's only one trade left in WISH stock, provided it can reclaim a key level.

Ocugen Stock Remains an All or Nothing Wager You Shouldn’t Make

By Thomas Niel, InvestorPlace Contributor
In so many words, the story's unchanged with OCGN stock. An all or nothing bet, with more pointing to "nothing," it's still best to stay away.

GameStop Keeps Lowering Costs, Should Be a Buy Closer to $100

By Mark R. Hake, CFA
GameStop keeps closing stores, lowering costs, but GME stock still needs to drop. GME stock is nearing an inflection point given its sales growth and cost-cutting but needs to drop at least 18% further.

Don’t Bother With Hyliion Stock Until They Can Create Revenue

By Stavros Georgiadis, CFA, InvestorPlace Contributor
HYLN stock had some brief excitement due to SPAC enthusiasm, but anyone left holding stock now has nothing to show for it.

Wait for a Bigger Discount in Nano Dimension Stock

By Mark R. Hake, CFA
NNDM stock seems to have $5.135 cash per share, but we don't know given poor disclosures, so defensive investors will wait to buy at $4.10 or a 20% discount.

GOEV Stock Remains a No-Go as the Company Remains a Laggard

By Alex Sirois, InvestorPlace Contributor
GOEV stock continues to play catch up after disappointing continually. There's little reason to believe in Canoo at this point.

Here Are 7 Stocks to Avoid Snapping Up in August

By Faizan Farooque, InvestorPlace Contributor
Many of the biggest losers in 2021 enjoyed big runs last year. But keeping up with shifting trends, here are some popular stocks to avoid.

As Long as Corsair’s ESG Issue Persists It Can Hamper CRSR Stock

By Will Ashworth, InvestorPlace Contributor
Corsair Gaming has lost 22% of its value in 2021. One reason CRSR stock is losing altitude has got to do with the composition of its board.

Clover Health Stock Harbors More Weeds Than Daisies

By Dana Blankenhorn, InvestorPlace Contributor
Clover Health claims to be a data-driven Medicare Advantage provider, but every health insurer is a data-driven Medicare Advantage provider.

Despite the Infrastructure Bill, ChargePoint Stock May Take Time to Recover

By Thomas Niel, InvestorPlace Contributor
With its valuation rich, and its federal spending catalyst already priced in, there's little reason to buy CHPT stock at today's prices.

Investors Are Still Looking at Exela Technologies for the Short Squeeze

By Dana Blankenhorn, InvestorPlace Contributor
Exela Technologies has sold $144 million in new shares so far this year, but still has $1.5 billion in debt and a market cap of $157 million. Meanwhile, XELA stock sits in the sights of hungry shorts.

Vaxart Is Another Risky Biotech Stock to Avoid Right Now

By Stavros Georgiadis, CFA, InvestorPlace Contributor
VRXT stock is highly overvalued. Investors are holding out for its Covid-19 vaccine, but it may not be approved in time to boost shares.

4 High Beta Stocks to Avoid on Possibility of a Market Correction

By Faisal Humayun, InvestorPlace Contributor
With the stock market looking frothy, these are four high beta stocks to avoid. Instead, go overweight on defensive stocks.

Avoid Unproven Meta Materials for Now

By Larry Ramer, InvestorPlace Contributor
Meta's new products may not pan out, and meme stocks are likely to continue to weaken, making MMAT stock unattractive.

7 Dividend Stocks to Avoid Until They Start to Shape Up Again

By Louis Navellier and the InvestorPlace Research Staff
When the economy and the markets get confusing, it's a good idea to turn to dividend stocks. Just make sure to pick the right ones.

With Zero Revenue, I Can’t Get Excited About Atossa

By Stavros Georgiadis, CFA, InvestorPlace Contributor
ATOS stock surged briefly in 2021 based on several catalysts, but none of them right now is supportive of its current price and valuation.
Load More Articles